Phenylketonuria

What Is Phenylketonuria?

Phenylketonuria (PKU) is a common autosomal recessive monogenic metabolic disorder caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene. Mutations impair the function of PAH enzyme, blocking normal phenylalanine (Phe) catabolism and resulting in systemic accumulation of phenylalanine in blood and organs. Typical clinical manifestations include severe developmental delay, neurological deficits, behavioral abnormalities, and recurrent seizures. The overall incidence in China is approximately 1 in 11,000, with a higher prevalence in northern populations than southern regions.

Pathogenesis

PKU arises from loss-of-function mutations in the PAH gene located at chromosomal locus 12q23.2. PAH catalyzes the critical hydroxylation reaction converting phenylalanine to tyrosine. Partial or complete loss of PAH activity disrupts the primary phenylalanine metabolic pathway, leading to pathological hyperphenylalaninemia. Elevated blood phenylalanine drives two major pathological cascades:

1. Excess phenylalanine shunts into alternative catabolic pathways, generating neurotoxic metabolites such as phenylpyruvate;
2. High phenylalanine concentrations competitively inhibit L-type amino acid transporter 1 (LAT-1), restricting cerebral uptake of essential amino acids including tryptophan and tyrosine. This disrupts synthesis of key neurotransmitters (serotonin, dopamine), impairs myelin formation, and induces chronic oxidative stress, ultimately triggering progressive, irreversible neuronal damage.

Ethnic Variants of PAH

In Chinese patients, PAH pathogenic variants are predominantly missense mutations (134 subtypes) and splice-site mutations (25 subtypes), clustered within exons 6, 7 and 12:

• The top hotspot variant is the exon 7 missense mutation p.R243Q (c.728G>A), accounting for 17.53% of all mutant alleles;
• Other prevalent variants with allele frequency >3%: p.EX6-96A>G (c.611A>G), p.V399V (c.1197A>T), p.R241C (c.721C>T), p.R111 (c.331C>T), p.Y356 (c.1068C>A), p.R413P (c.1238G>C), IVS4-1G>A (c.442-1G>A).

For Caucasian populations of European descent, major PKU hotspots reside in exon 12 and intron 12, chiefly R408W and IVS12+1G>A.

Figure Source: Advances in Phenylketonuria Research

Gene Therapy Strategies

1. AAV-Mediated Gene Therapy

Adeno-associated viral vectors deliver functional wild-type PAH cDNA into hepatocytes, where the transgene persists as episomal DNA to sustain long-term PAH expression. PTC Therapeutics’ PTC-AAT program has advanced into clinical trials. Preliminary clinical data demonstrated durable reduction of blood phenylalanine levels lasting multiple years in adult PKU patients.

2. Gene Editing Therapy

Precision gene editing nucleases cleave mutated genomic loci, enabling correction of pathogenic sequences via endogenous cellular DNA repair machinery supplied with wild-type repair templates. Alternatively, safe-harbor locus integration of full-length normal PAH achieves stable, sustained hepatic PAH expression.

Preclinical Mouse Models for PKU Research

1. Pah^enu2 Knock-In Mice Carry the c.835T>C (p.F263S) point mutation in the murine Pah gene. This strain recapitulates core human PKU neurobiological phenotypes, including cognitive impairment, hyperactivity, anxiety-like behaviors, and depleted cerebral monoamine neurotransmitters such as serotonin.
2. Liver-Specific Conditional Pah Knockout Mice Hepatic-restricted ablation of Pah, designed to evaluate whether liver-targeted PAH restoration alone is sufficient to rescue systemic PKU pathology.
3. Pah^-/- Global Knockout Mice Complete loss of endogenous phenylalanine hydroxylase function, exhibiting severe persistent hyperphenylalaninemia that recapitulates the core metabolic signature of human PKU.

VeloGene Biotechnology Accelerates Rare Disease Gene Therapy R&D

Gene therapy delivers transformative therapeutic prospects for rare inherited disorders, yet preclinical mechanism research and therapeutic efficacy validation are fully dependent on standardized, well-characterized animal models.

Powered by our proprietary TurboMice™ technology, VeloGene Biotechnology has generated a comprehensive portfolio of rare disease gene-edited mouse models. TurboMice™ resolves two longstanding technical bottlenecks of traditional transgenic strain construction: prolonged breeding cycles and low success rates for complex multi-locus genetic modifications. The platform supports precise editing of nearly any target genomic locus and generates fully homozygous gene-edited mouse lines directly from embryonic stem cells in as little as 2 months.

VeloGene Biotechnology provides custom PKU mouse models tailored to individual experimental demands, including Pah^enu2 knock-in mice, liver-specific conditional Pah knockout mice, and global Pah^-/- knockout mice. Academic and industrial researchers are welcome to contact our technical team for project consultations!